Letroz Tablet contains Letrozole 2.5 mg, a non-steroidal aromatase inhibitor used primarily in the treatment of hormone receptor-positive breast cancer in postmenopausal women. Letrozole works by selectively inhibiting the aromatase enzyme, which is responsible for the peripheral conversion of androgens to estrogens. By reducing estrogen levels, Letrozole effectively deprives estrogen-dependent breast cancer cells of the hormone necessary for their growth and proliferation. This medication is indicated for adjuvant treatment of early breast cancer, advanced or metastatic breast cancer, and as a first-line therapy in hormone receptor-positive breast cancer patients. Letrozole is administered orally, typically once daily, and dosage should be individualized based on clinical response and tolerability. Common adverse effects include hot flashes, arthralgia, fatigue, and nausea, while serious side effects may involve bone density reduction and increased risk of osteoporosis; therefore, monitoring bone health during therapy is recommended. Letrozole is contraindicated in premenopausal women, pregnancy, and hypersensitivity to the active substance. It is essential to use Letrozole under strict medical supervision with regular follow-up to assess therapeutic efficacy and manage potential side effects.